Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Zevra Therapeutics (ZVRA) EPS (Basic) (2016 - 2025)

Historic EPS (Basic) for Zevra Therapeutics (ZVRA) over the last 11 years, with Q3 2025 value amounting to -$0.01.

  • Zevra Therapeutics' EPS (Basic) rose 9855.07% to -$0.01 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.48, marking a year-over-year increase of 12274.88%. This contributed to the annual value of -$2.28 for FY2024, which is 7548.14% down from last year.
  • According to the latest figures from Q3 2025, Zevra Therapeutics' EPS (Basic) is -$0.01, which was up 9855.07% from $1.24 recorded in Q2 2025.
  • Zevra Therapeutics' 5-year EPS (Basic) high stood at $1.24 for Q2 2025, and its period low was -$2.49 during Q1 2021.
  • Over the past 5 years, Zevra Therapeutics' median EPS (Basic) value was -$0.36 (recorded in 2022), while the average stood at -$0.31.
  • As far as peak fluctuations go, Zevra Therapeutics' EPS (Basic) tumbled by 62000.0% in 2022, and later surged by 35833.33% in 2025.
  • Zevra Therapeutics' EPS (Basic) (Quarter) stood at $0.05 in 2021, then surged by 220.0% to $0.16 in 2022, then crashed by 437.5% to -$0.54 in 2023, then tumbled by 43.1% to -$0.77 in 2024, then skyrocketed by 98.71% to -$0.01 in 2025.
  • Its last three reported values are -$0.01 in Q3 2025, $1.24 for Q2 2025, and -$0.06 during Q1 2025.